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Abstract
Thirteen human papillomavirus (HPV) genotypes have been judged to be carcinogenic or probably
carcinogenic, and the cause of virtually all cervical cancer worldwide. Other HPV genotypes could
possibly be involved. Although the inclusion of possibly carcinogenic HPV genotypes may hurt test
specificity, it may indirectly increase the reassurance following a negative HPV test (i.e. the negative
predictive value of an HPV test for cervical precancer and cancer). The future of cervical cancer
screening in low-resource setting, however, may include once-in-a-lifetime, low-cost and rapid HPV
testing. However, the tradeoff o f  m o r e  f a l s e  p o s i tives for greater reassurance may not be
acceptable if the local infrastructure cannot manage the screen positives. Now is the time for the
community of scientists, doctors, and public health advocates to use the data presented at the
100th International Agency for Research on Cancer monograph meeting to rationally decide the
target HPV genotypes for the next generation of HPV tests for use in high-resource and low-
resource settings. The implications of including possibly HPV genotypes on HPV test performance,
also for guidance on the use of these tests for cervical cancer prevention programs, are discussed.
Commentary
Periodically the International Agency for Research on
Cancer (IARC) convenes a meeting of cancer experts to
review and update the evidence regarding potential car-
cinogens. In February of 2009, the meeting for the 100th
IARC monograph convened on the carcinogenicity of bio-
logical agents, including human papillomavirus (HPV),
now widely acknowledged as the obligate cause of cervical
cancer and the important cause of other epithelial cancers,
updating the evidence from the 90th monograph meeting
in 2005 [1,2]. One of the primary goals of this meeting
was to examine the evidence for potential for each of the
more than 100 HPV genotypes to cause cancer. The meet-
ing report by Bouvard et al. [3] provides an overview of the
meeting for all biological agents and highlights that cervi-
cal cancer is caused by HPV types that belong to a few phy-
logenetically related "high-risk" species (apha-5, 6, 7, 9
and 11) of the mucosotropic alpha genus. Schiffman et al.
in the accompanying article provide the rationale that was
used at the meeting to classify the mucosotropic HPV
types as cancer-associated (carcinogenic) or not. Based on
large case series, meta-analyses, and laboratory data of
mechanistic studies, twelve HPV genotypes (HPV16, 18,
31, 33, 35, 39, 45, 51, 52, 56, 58, and 59) were deemed
carcinogenic and HPV68 was considered probably carci-
nogenic.
One of the important outcomes of the meeting was the
downgrading of HPV66 from the category of probably car-
cinogenic (Group 2A), as judged in 2005, to possibly car-
cinogenic (Group 2B), which also includes HPV
genotypes HPV26, HPV53, HPV67, HPV70, HPV73, and
HPV82. As explained by Schiffman et al. [4,5], these HPV
genotypes had limited epidemiological evidence to cause
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cancer but are genetically related to other HPV genotypes
that are carcinogenic. Unlike for HPV68, which is known
to maintain a cancer cell line (ME 180), there are as yet
only scarce laboratory data showing carcinogenic proper-
ties of few of the HPV genotypes classified as possibly car-
cinogenic (Group 2B) [3]. Furthermore, unfortunately,
the available laboratory data did not provide information
to understand the differences in carcinogenetic behavior
between the HPV genotypes that belong to the "high-risk"
alpha species [6,7].
Temporarily categorizing HPV66 as probably carcino-
genic during the four-year interval meetings impacted the
development of new clinical HPV assay. In 2005, there
was only one FDA-approved HPV DNA test, hybrid cap-
ture 2 (hc2; Qiagen (formerly Digene), Gaithersburg,
Maryland, USA), which targets the 13 certain and proba-
bly carcinogenic HPV genotypes as a pool of HPV geno-
types. In 2009, one additional test, Cervista (Third Wave
Technologies, Hologic, Inc., Madison, Wisconsin, USA),
received FDA approval http://www.fda.gov/cdrh/mda/
docs/P080015.html and several other assays from other
companies are being evaluated in clinical trials. Most have
included HPV66 in their panel of targeted HPV genotypes.
What is the impact of including HPV66 in clinical tests?
The lifecycle of these tests, from development to valida-
tion, is 10 years or more. As a consequence, there will be
a generation of HPV tests (even some that are not now in
clinical trials but too far along in the formulation phase to
alter) that include HPV66 and in theory will be slightly
less specific than what might otherwise be achieved. Thus,
more women will test positive for HPV when used in pri-
mary screening or as triage/reflex test for equivocal (atyp-
ical squamous cells of undetermined significance [ASC-
US]) cytology.
Worldwide, the prevalence of HPV66 estimated to be
0.4% (95%CI = 0.3–0.4%) although there are some
regional variations in its prevalence [8]. Therefore, an
additional 1 in 250 all women screened (400 in 100,000
women) will be called carcinogenic HPV positive because
of the inclusion of HPV66. For simplicity, the contribu-
tion of HPV66 to testing positive has ignored the
unknown fraction of HPV66 positives co-infected with
carcinogenic and probable carcinogenic HPV genotypes.
Of those who are HPV66 positive, perhaps another =
0.5% will have a concurrent diagnosis of cervical intraep-
ithelial grade 2 (CIN2), equivocal precancer [9,10], or
CIN3, more certain precancer, both of which are typically
treated by excision or ablative procedures. Thus, the inclu-
sion of HPV66 will result in the identification of HPV66-
related CIN2/3 in roughly 2 in 100,000 women screened
with the current HPV tests. Whether these HPV66-related
CIN2/3 cases are clinically important, i.e. have invasive
potential, or not remains unclear.
Future meetings will no doubt try to resolve whether these
borderline carcinogenic HPV genotypes (HPV26, HPV53,
HPV66, HPV67, HPV70, HPV73, and HPV82) are cancer
causing or not. Integrative epidemiologic and further lab-
oratory approaches will be needed for clarification. New
investigative tools, such as micro-dissection of the lesion
and HPV genotyping or in situ methods if they ever prove
to be sufficiently sensitive, and genotype-specific detec-
tion of HPV E6/E7 transcripts or protein [11,12] may help
to assign causal HPV genotypes.
In the end, perhaps resolving this issue of which of the
borderline HPV genotypes are carcinogenic does not mat-
ter except for academic albeit important biological rea-
sons: to understand the nature of HPV carcinogenicity and
its relationship to viral genetics and phylogenetics [4]. We
already know enough to decide which HPV genotypes to
include in clinical HPV tests. As shown by others [5] using
a receiver-operator curve (ROC)-like approach and CIN3
as the intermediate cancer endpoint, after including 8–10
most carcinogenic HPV genotypes there was only a slight
increase in sensitivity and a larger cost in specificity with
each additional HPV genotype included. However, CIN3
is subject to some diagnostic error [13,14], and some
questionable or non-carcinogenic HPV genotypes can
cause CIN3 that has little potential for invasion [14].
Thus, one would expect even greater clarity by redoing this
analysis with a cancer endpoint using the accumulated
data presented at the 100th IARC monograph meeting.
Experts then could come to a consensus about what is an
acceptable tradeoff in sensitivity versus specificity vis-à-vis
which HPV genotypes to include in clinical assays, accept-
ing the notion that no test will achieve perfect sensitivity
and that poor specificity has important implications,
including potential unnecessary treatment, which can
cause negative reproductive outcomes [15,16].
As a first approximation, a simple version of this ROC-like
analysis approach based on previously reported data
[8,17] is shown in Figure 1. Notably, as previously noted
[5], there is very little gain in sensitivity after the inclusion
of the first ~10 HPV genotypes. Of note, the addition of
the possible HPV genotypes decreases specificity by
approximately 2%, or 2,000 additional HPV positives per
100,000 women, with virtually no benefit. Notably, most
of these possible HPV genotypes (HPV53, HPV66,
HPV67, HPV70, HPV73, and HPV82) are commonly
detected by hc2 as the result of less than perfect targeting
of the carcinogenic and possibly carcinogenic HPV geno-
types [18]. Despite the cross-reactivity to these weakly car-
cinogenic or non-carcinogenic HPV genotypes, hc2 has
been proposed as the current benchmark for HPV test per-Infectious Agents and Cancer 2009, 4:7 http://www.infectagentscancer.com/content/4/1/7
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formance [19,20]. More fidelity for the important HPV
genotypes will improve the performance of HPV tests by
reducing the number of false positive results. A more for-
mal ROC-like analysis of the data from the 100th IARC
monograph [3] is needed to confirm these observations.
The inclusion or exclusion of borderline carcinogenic
HPV genotypes in a clinical assay for carcinogenic HPV
becomes moot if robust strategies for management (risk
stratification) of test positives become available. That is,
there would be no significant penalty to include some of
these borderline HPV genotypes if there was downstream,
specific method of triaging HPV-positive women to sepa-
rate those in need of immediate colposcopy versus those
who could be monitored by repeat screening in a year or
two. The key is good stratification of risk for cervical pre-
cancer and cancer, and consistent, appropriate manage-
ment of that risk [21]. Some approaches, such as using
cytology [22], HPV genotyping [23], and/or p16 immu-
nostaining [24], look promising but need further valida-
tion. New, as of yet undiscovered, biomarkers may
provide still better solutions.
The impact of adding individual carcinogenic, probable carcinogenic, and possible carcinogenic human papillomavirus (HPV)  genotypes to a clinical HPV assay Figure 1
The impact of adding individual carcinogenic, probable carcinogenic, and possible carcinogenic human papillo-
mavirus (HPV) genotypes to a clinical HPV assay. The impact of adding individual carcinogenic, probable carcinogenic, 
and possible carcinogenic human papillomavirus (HPV) genotypes to a clinical HPV assay was estimated using a receiver-opera-
tor curve (ROC)-like approach of stepwise adding individual HPV genotypes according to their prevalence, from most preva-
lent (HPV16) to least (HPV53), in cervical cancer [8,17]. Relative sensitivity (true positive fraction) was estimated based on 
those prevalences using the following assumptions: 1) HPV genotypes act independently such that cancers with multiple HPV 
genotypes detected were proportionally attributable to the HPV genotypes according to their overall prevalence; and 2) all 
cervical cancer is caused by HPV, and false negative results were independent of HPV genotype. Therefore, it was assumed that 
all cancers would have tested HPV positive with a perfectly sensitive test, and the relative contribution of each HPV genotype 
to cervical was a constant (although the absolute number increased). The relative false positive fraction, 1-Specificity, was esti-
mated from the prevalence of individual HPV genotypes in the cytologic normal population, ignoring the overlap between HPV 
genotypes due to multi-HPV genotype infections (~25% of HPV positives).Infectious Agents and Cancer 2009, 4:7 http://www.infectagentscancer.com/content/4/1/7
Page 4 of 5
(page number not for citation purposes)
Although the inclusion of possibly carcinogenic HPV gen-
otypes may hurt test specificity, it may indirectly increase
the reassurance following a negative HPV test i.e. the neg-
ative predictive value of an HPV test for cervical precancer
and cancer. Because non-carcinogenic and carcinogenic
HPV infections alike are sexually transmitted, identifica-
tion of women with borderline carcinogenic or non-carci-
nogenic HPV identifies a subset of higher-risk women
who are more likely to subsequently acquire a new carci-
nogenic HPV infection. That is, women who are HPV pos-
itive for any HPV type at any given time point represent a
sub-group that engages in more risky behavior, such as
having more sexual partners, or have a partner(s) who is
more likely to do so.
The future of cervical cancer screening in low-resource set-
ting may include once-in-a-lifetime, low-cost and rapid
HPV testing [25,26]. The inclusion/exclusion of HPV gen-
otypes, and therefore the tradeoff of sensitivity versus spe-
cificity, will depend greatly on the strategy for following-
up and managing the screen positives and the resources to
do so. Prevention programs that will require the use of the
more traditional screen, colposcopic evaluation of screen
positives, and treatment of women with precancer will
need sufficient numbers of highly-trained colposcopists
to handle the clinical volume of screen positives, which
could approach 10–15% of the population in many loca-
tions [27]. The tradeoff of more false positives for greater
reassurance may not be an acceptable if the local infra-
structure cannot manage the screen positives.
Other prevention programs may adopt screen and treat
approaches, in which all screen positives undergo some
treatment. For example, HPV-positive women could then
be evaluated by visual inspection with acetic acid to
decide the best treatment option: chemotherapy or pallia-
tive care for women with obvious cancer, surgical lesion
excision (by a physician at a regional medical center) for
large precancerous lesions that are not amenable to cryo-
therapy, and cryotherapy for all other HPV-positive
women. Such an algorithm would only be applied to pop-
ulations of older women, more than 10–15 years past the
population median age of sexual debut, to minimize the
over-treatment of mostly transient HPV infections in
reproductive-age women. In general, because HPV-posi-
tive women will not undergo any further characterizations
such as colposcopy or a secondary test, there should be a
greater emphasis on specificity i.e. inclusion of only the
certain carcinogenic HPV genotypes. However, there is
some evidence to suggest that cryotherapy provides a sec-
ondary benefit of reducing the likelihood of acquiring
new HPV infections post-treatment [28], which might
increase the acceptability of over-treatment of screen pos-
itives when applied once to a population.
In the end, it seems unlikely that companies that develop
HPV tests will tailor their tests to individual country
needs. Now is the time for the community of scientists,
doctors, and public health advocates to use the data pre-
sented at the 100th IARC monograph meeting to rationally
decide the target HPV genotypes for the next generation of
HPV tests for use in high-resource and low-resource set-
tings. And provide guidance on the use of these tests for
cervical cancer prevention programs. However, the adop-
tion of any cervical cancer screening and prevention pro-
gram will depend on its social and cultural acceptance as
well as available resources and the political willpower to
implement it.
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